EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
EyePoint (Nasdaq:EYPT) granted non-statutory stock options as inducement awards to eight new employees under NASDAQ Listing Rule 5635(c)(4), outside its 2023 Long-Term Incentive Plan.
The options cover up to 158,100 shares at an exercise price of $12.35, with a ten-year term and four-year vesting.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – EYPT
On the day this news was published, EYPT declined 5.26%, reflecting a notable negative market reaction. Argus tracked a trough of -5.6% from its starting point during tracking. This price movement removed approximately $57M from the company's valuation, bringing the market cap to $1.04B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
EYPT was down 6.72% while peers were mixed: QURE -1.28%, URGN -1.64%, but OCS +1.34%, PRAX +1.42%, UPB +5.82%, pointing to a stock-specific move rather than a sector-wide pattern.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 14 | Phase 3 DSMC update | Positive | -1.4% | Third positive DSMC recommendation for DURAVYU Phase 3 wet AMD trials. |
| May 06 | Q1 2026 earnings | Neutral | -2.9% | Q1 2026 results with higher operating spend and ongoing Phase 3 programs. |
| Apr 29 | Earnings date notice | Neutral | -4.5% | Announcement of date and webcast details for Q1 2026 results. |
| Apr 16 | Inducement option grants | Neutral | +0.8% | Inducement options for fourteen new employees under NASDAQ Rule 5635(c)(4). |
| Mar 16 | Inducement option grants | Neutral | +1.6% | Inducement options for six new employees under NASDAQ Rule 5635(c)(4). |
Recent news, including positive clinical and routine corporate updates, has often been followed by flat-to-negative price moves, showing several instances of divergence on seemingly favorable headlines.
Over the last two months, EyePoint has reported multiple milestones, including a third consecutive positive DSMC recommendation for its Phase 3 DURAVYU wet AMD trials and Q1 2026 financials with substantial investment in late-stage programs. The stock also saw repeated inducement option grants in March, April, and now May 2026, reflecting ongoing hiring. Despite clinically positive developments and routine corporate actions, shares have often traded lower or only modestly higher following these announcements.
Market Pulse Summary
The stock moved -5.3% in the session following this news. A negative reaction despite routine inducement grants fits a backdrop where even positive clinical developments, such as the recent Phase 3 DSMC update, previously coincided with share price weakness. The stock had already been trading below its 200-day MA, and recent filings highlight continued investment and insider selling activity. In this context, option grants may have reinforced dilution concerns, and prior patterns suggest that news flow alone has not consistently supported sustained strength after corporate announcements.
Key Terms
non-statutory stock options financial
NASDAQ Listing Rule 5635(c)(4) regulatory
exercise price financial
vest financial
AI-generated analysis. Not financial advice.
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 158,100 shares of EyePoint common stock to eight new employees. The stock options were granted on May 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media:
Helen O’Gorman
FTI Consulting
helen.ogorman@fticonsulting.com
